The global non-Hodgkin lymphoma (NHL) therapeutics market, valued at USD 9.05 billion in 2024, is projected to expand at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2034. This robust growth trajectory is primarily fueled by rising cancer incidence, increasing healthcare expenditures, and the rapid adoption of targeted therapies across developed and emerging markets. As the...